118 related articles for article (PubMed ID: 28009326)
41. Evaluating the effectiveness of RNA in-situ hybridization for detecting lung adenocarcinoma with anaplastic lymphoma kinase rearrangement.
Nakajima N; Yoshizawa A; Kondo K; Rokutan-Kurata M; Hirata M; Furuhata A; Sumiyoshi S; Sonobe M; Menju T; Momose M; Fujimoto M; Date H; Haga H
Histopathology; 2017 Jul; 71(1):143-149. PubMed ID: 28231386
[TBL] [Abstract][Full Text] [Related]
42. Management and future directions in non-small cell lung cancer with known activating mutations.
Gerber DE; Gandhi L; Costa DB
Am Soc Clin Oncol Educ Book; 2014; ():e353-65. PubMed ID: 24857124
[TBL] [Abstract][Full Text] [Related]
43. Assessment of cytology based molecular analysis to guide targeted therapy in advanced non-small-cell lung cancer.
Li W; Zhang Z; Guo L; Qiu T; Ling Y; Cao J; Guo H; Zhao H; Li L; Ying J
Oncotarget; 2016 Feb; 7(7):8332-40. PubMed ID: 26789109
[TBL] [Abstract][Full Text] [Related]
44. ALK testing in lung adenocarcinoma: technical aspects to improve FISH evaluation in daily practice.
Martin V; Bernasconi B; Merlo E; Balzarini P; Vermi W; Riva A; Chiaravalli AM; Frattini M; Sahnane N; Facchetti F; Mazzucchelli L; Sessa F; Tibiletti MG
J Thorac Oncol; 2015 Apr; 10(4):595-602. PubMed ID: 25514802
[TBL] [Abstract][Full Text] [Related]
45. [ALK gene fusion associated non-small cell lung cancer: automated immunostainer detection and clinicopathologic perspectives].
Shen Q; Pan Y; Yu B; Shi S; Liu B; Xu Y; Wang Y; Xia Q; Rao Q; Lu Z; Shi Q; Zhou X
Zhonghua Bing Li Xue Za Zhi; 2015 Mar; 44(3):164-9. PubMed ID: 26268749
[TBL] [Abstract][Full Text] [Related]
46. Concomitant Presence of EGFR and ALK Fusion Gene Mutation in Adenocarcinoma of Lung: A Case Report and Review of the Literature.
Thumallapally N; Yu H; Farhan M; Ibrahim U; Odiami M
J Pharm Pract; 2018 Apr; 31(2):244-248. PubMed ID: 28438075
[TBL] [Abstract][Full Text] [Related]
47. Copy number status and mutation analyses of anaplastic lymphoma kinase (ALK) gene in 90 sporadic neuroblastoma tumors.
Bagci O; Tumer S; Olgun N; Altungoz O
Cancer Lett; 2012 Apr; 317(1):72-7. PubMed ID: 22085494
[TBL] [Abstract][Full Text] [Related]
48. An Anaplastic Lymphoma Kinase Immunohistochemistry-Negative but Fluorescence In Situ Hybridization-Positive Lung Adenocarcinoma Is Resistant to Crizotinib.
Shi R; Varella-Garcia M; Li M; Ludkovski O; Danesh A; Ng C; Pham NA; Pugh T; Shepherd FA; Tsao MS
J Thorac Oncol; 2016 Dec; 11(12):2248-2252. PubMed ID: 27613526
[TBL] [Abstract][Full Text] [Related]
49. [Anaplastic lymphoma kinase-positive adenocarcinoma of lung: a cytopathologic analysis].
Chen Y; Gao L; Wang Y; Gui X; Zhang H; Wang L; Gu L; Feng L; Wu J; Yang W; Song Y; Zeng H; Zhang J; Bai Q; Zhou X; Ping B
Zhonghua Bing Li Xue Za Zhi; 2015 Sep; 44(9):628-32. PubMed ID: 26705277
[TBL] [Abstract][Full Text] [Related]
50. Clinical Validation of a Novel Commercial Reverse Transcription-Quantitative Polymerase Chain Reaction Screening Assay for Detection of ALK Translocations and Amplifications in Non-Small Cell Lung Carcinomas.
Liu C; Pepper K; Hendrickson H; Cagle PT; Portier BP
Arch Pathol Lab Med; 2016 Jul; 140(7):690-3. PubMed ID: 26599807
[TBL] [Abstract][Full Text] [Related]
51. Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization.
Ali SM; Hensing T; Schrock AB; Allen J; Sanford E; Gowen K; Kulkarni A; He J; Suh JH; Lipson D; Elvin JA; Yelensky R; Chalmers Z; Chmielecki J; Peled N; Klempner SJ; Firozvi K; Frampton GM; Molina JR; Menon S; Brahmer JR; MacMahon H; Nowak J; Ou SH; Zauderer M; Ladanyi M; Zakowski M; Fischbach N; Ross JS; Stephens PJ; Miller VA; Wakelee H; Ganesan S; Salgia R
Oncologist; 2016 Jun; 21(6):762-70. PubMed ID: 27245569
[TBL] [Abstract][Full Text] [Related]
52. New insights into anaplastic lymphoma kinase-positive nonsmall cell lung cancer.
Dubey AP; Pathi N; Viswanath S; Rathore A; Pathak A; Sud R
Indian J Cancer; 2017; 54(1):203-208. PubMed ID: 29199691
[TBL] [Abstract][Full Text] [Related]
53. ALK status testing in non-small-cell lung carcinoma by FISH on ThinPrep slides with cytology material.
Minca EC; Lanigan CP; Reynolds JP; Wang Z; Ma PC; Cicenia J; Almeida FA; Pennell NA; Tubbs RR
J Thorac Oncol; 2014 Apr; 9(4):464-8. PubMed ID: 24736067
[TBL] [Abstract][Full Text] [Related]
54. Amplification but not translocation of anaplastic lymphoma kinase is a frequent event in oesophageal cancer.
Schoppmann SF; Streubel B; Birner P
Eur J Cancer; 2013 May; 49(8):1876-81. PubMed ID: 23490651
[TBL] [Abstract][Full Text] [Related]
55. [Association between the ALK Gene Status and the Efficacy of First-line
Pemetrexed Chemotherapy in Patients with Advanced Lung Adenocarcinoma].
Chen M; Cao H; Ji Y; Mao Y; Shen S; Li X
Zhongguo Fei Ai Za Zhi; 2017 Nov; 20(11):732-736. PubMed ID: 29167001
[TBL] [Abstract][Full Text] [Related]
56. Concomitant EGFR mutation and ALK rearrangement in lung adenocarcinoma is more frequent than expected: report of a case and review of the literature with demonstration of genes alteration into the same tumor cells.
Baldi L; Mengoli MC; Bisagni A; Banzi MC; Boni C; Rossi G
Lung Cancer; 2014 Nov; 86(2):291-5. PubMed ID: 25312989
[TBL] [Abstract][Full Text] [Related]
57. Comparison of reverse transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubule-associated proteinlike 4-anaplastic lymphoma kinase fusion-positive non-small cell lung carcinoma: implications for optimal clinical testing.
Wallander ML; Geiersbach KB; Tripp SR; Layfield LJ
Arch Pathol Lab Med; 2012 Jul; 136(7):796-803. PubMed ID: 22742552
[TBL] [Abstract][Full Text] [Related]
58. HIP1-ALK, a novel fusion protein identified in lung adenocarcinoma.
Hong M; Kim RN; Song JY; Choi SJ; Oh E; Lira ME; Mao M; Takeuchi K; Han J; Kim J; Choi YL
J Thorac Oncol; 2014 Mar; 9(3):419-22. PubMed ID: 24518094
[TBL] [Abstract][Full Text] [Related]
59. Validation of ALK/ROS1 Dual Break Apart FISH Probe probe in non-small-cell lung cancer.
Lim SM; Chang H; Cha YJ; Liang S; Tai YC; Li G; Pestova E; Policht F; Perez T; Soo RA; Park WY; Kim HR; Shim HS; Cho BC
Lung Cancer; 2017 Sep; 111():79-83. PubMed ID: 28838404
[TBL] [Abstract][Full Text] [Related]
60. ALK inhibitors in the treatment of advanced NSCLC.
Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]